 |
36 Diseases |  |
5 Trials |
|
5 Trials |  |
637 News |  |
| «12345678910» |
- [VIRTUAL] Direct antivirals can achieve a cure in all patients with chronic hepatitis C due to genotype 5. A French multicentre study. (Poster area) - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_1227;
A high SVR12, 99% (138/139) in intention to treat and 100% (138/138) per protocol, was achieved in HCV GT5 patients treatedwith a DAA-regimen. This cohort shows that the combination treatments of SOF/LDV, SOF/VEL and GLE/PIB are very efficient in patients infected with HCV GT5.
- || Zepatier (grazoprevir/elbasvir) / Merck (MSD), Olysio (simeprevir) / J&J, Medivir
Clinical, Journal: Acute interstitial nephritis following treatment with direct-acting antiviral agents in hepatitis C virus-infected patients: A case series. (Pubmed Central) - Apr 7, 2021
These results are consistent with earlier studies demonstrating the efficacy of the DAAs in HCV-infected CKD patients. Of note, the demonstration of AIN in these patients may explain some of the AKI events reported with the use of DAAs in patients with CKD.
- || ribavirin / Generic mfg.
Clinical, Journal: Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease. (Pubmed Central) - Mar 11, 2021
All-oral, interferon-free therapy with DAAs for chronic HCV in mild-to-moderate CKD was effective and well-tolerated in a 'real-world' clinical setting. Studies are in progress to address whether sustained viral response translates into better survival in this population.
- | Sunvepra (asunaprevir) / BMS
Journal: Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: In Silico Modeling and In Vitro Screening. (Pubmed Central) - Mar 9, 2021
Molecular docking and MD simulations were then performed to investigate the effects of these ligands on M3CLpro and to provide insights into the chemical environment of the ligand binding site. Our findings and observations are offered to help guide the design of possible potent protease inhibitors and aid in coping with the COVID-19 pandemic.
- | Journal: SARS-CoV-2 and SARS-CoV: Virtual Screening of Potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12). (Pubmed Central) - Mar 3, 2021
Eight compounds (Nilotinib, Saquinavir, Tipranavir, Lonafarnib, Tegobuvir, Olysio, Filibuvir and Cepharanthine) were selected for binding free energy calculations based on virtual screening and docking scores. All eight compounds can combine well with NSP12-NSP7-NSP8 in the crystal structure, providing drug candidates for the treatment and prevention of COVID-19 and SARS.
- || Copegus (ribavirin) / Bausch Health, Olysio (simeprevir) / J&J, Medivir
Clinical, Journal: A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil. (Pubmed Central) - Feb 11, 2021
We conducted a real-life study on liver transplant recipients with CHC treated with a combination of sofosbuvir (SOF) and daclatasvir (DCV) or simeprevir (SIM), with or without RBV, followed-up for 12 to 24 weeks...There was a significant reduction in ALT, AST, GGT and FA levels, or the APRI index after 4 weeks of treatment, which remained until 12/24 weeks post-treatment. DAA treatment of CHC in liver-transplanted patients achieved a high SVR rate and resulted in the normalization of serum levels of liver enzymes.
- | Olysio (simeprevir) / J&J, Medivir
Journal: Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection. (Pubmed Central) - Feb 4, 2021
This report raises a question about a possible relationship between treatment with DAAs and development of extrahepatic malignancies. Thus, data collection from larger cohorts is critical to determine the relationship possibility.
- | Olysio (simeprevir) / J&J, Medivir, Xofluza (baloxavir marboxil) / Roche, Shionogi
Journal, Combination therapy: Combination and tricombination therapy to destabilize the structural integrity of COVID-19 by some bioactive compounds with antiviral drugs: insights from molecular docking study. (Pubmed Central) - Jan 14, 2021
In this study, we aim to find antagonists that may inhibit the activity of the three major viral targets: SARS-CoV-2 3-chymotrypsin-like protease (6LU7), SARS-CoV-2 spike protein (6VYB), and a host target human angiotensin-converting enzyme 2 (ACE2) receptor (1R42), which is the entry point for the viral encounter, were studied with the prospects of identifying significant drug candidate(s) against COVID-19 infection...Hence, we studied the combination and tricombination therapy between bioactive compounds which have the best binding affinity and some antiviral drugs like chloroquine, hydroxychloroquine, azithromycin, simeprevir, baloxavir, lopinavir, and favipiravir to show the effect of combination and tricombination therapy to disrupt the stability of the three major viral targets that are mentioned previously...All results confirmed that caulerpin can be utilized as a combination and tricombination therapy along with the studied antiviral drugs for disrupting the stability of the three major viral receptors (6LU7, 6VYB, and 1R42). The online version contains supplementary material available at 10.1007/s11224-020-01723-5.
- || grazoprevir (MK-5172) / Merck (MSD), Sunvepra (asunaprevir) / BMS
Review, Journal: Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review. (Pubmed Central) - Jan 13, 2021
For the majority of these drugs, direct clinical evidence on their efficacy for the treatment of COVID-19 is lacking. Future clinical studies examining these drugs might come to conclude, which can be more useful to inhibit COVID-19 progression.
- | Sunvepra (asunaprevir) / BMS, Ledipasvir (GS-5885) / Gilead
Preclinical, Journal: Estimating efflux transporter-mediated disposition of molecules beyond the rule of five (bRo5) using transporter gene knockout rats. (Pubmed Central) - Jan 6, 2021
Moreover, results on the absorption rate-time profile suggests that efflux transporters are constantly active during the absorption period in rats. Transporter knockout rats are a useful in vivo ADME tool for estimating the transporter-mediated disposition of bRo5 molecules in drug discovery.
- || Review, Journal: Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review. (Pubmed Central) - Dec 23, 2020
DOACs and DAAs are under-investigated for DDI risk. Real-world studies are needed to assess the clinical relevance of the pharmacokinetic interactions with dabigatran and describe the actual spectrum of possible DDIs between DAAs and other DOACs.
- || Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: The benefits of a public pharmacist service in chronic hepattis C treatment: The real-life results of sofosbuvir-based therapy. (Pubmed Central) - Dec 19, 2020
Real-world studies are needed to assess the clinical relevance of the pharmacokinetic interactions with dabigatran and describe the actual spectrum of possible DDIs between DAAs and other DOACs. The clinical pharmacist services provided by the UPh was beneficial to patients treated for CHC with the sofosbuvir-based therapy.
- | Sunvepra (asunaprevir) / BMS
Journal: Zika Virus NS3 Protease Pharmacophore Anchor Model and Drug Discovery. (Pubmed Central) - Dec 16, 2020
Additionally, the PA model anchors aided in the exploration of inhibitor binding mechanisms. In conclusion, our PA model serves as a promising guide map for ZIKV protease targeted drug discovery and the identified 'previr' FDA drugs are promising for anti-ZIKV treatments.
- | paritaprevir/ritonavir (ABT-450/r) / AbbVie
Journal: The potential of Paritaprevir and Emetine as inhibitors of SARS-CoV-2 RdRp. (Pubmed Central) - Dec 8, 2020
The recent elucidation of the experimental structure of SARS-CoV-2 RdRp enzyme complexed with triphosphate form of Remdesivir (RTP) has opened an avenue for structure-based identification of potent inhibitors...The top 3 hits among the FDA approved drugs were Paritaprevir (D33), Rilpivirine (D19) and Simeprevir (D31) which scored binding energies between -8.08 kcal/mol and -10.46 kcal/mol...Further, the physicochemical properties of the molecules were evaluated. These identified potential inhibitors warrant further experimental investigations before their acceptance as drug candidates for the treatment of the disease.
- | ritonavir / Generic mfg.
FDA event, Journal: Computation screening and molecular docking of FDA approved viral protease inhibitors as a potential drug against COVID-19. (Pubmed Central) - Nov 28, 2020
The findings showed that the four selected FDA approved drugs can be potent inhibitors against COVID-19; among them, Temoporfin may be more potent for the treatment of the disease. Based on the findings, it is recommended that in-vitro and in-vivo evaluations be conducted to determine the effectiveness of these drugs against COVID-19.
- || Olysio (simeprevir) / J&J, Medivir
Clinical, Journal: Microenvironment improvement protocol for the sensitive spectrofluorimetric determination of an hepatitis C virus antiviral (Simeprevir): application to human plasma. (Pubmed Central) - Nov 12, 2020
The limits of detection and quantitation were 21 and 64 ng ml , respectively. The present method was effectively applied to quantify SPV content in pharmaceutical tablets and human plasma spiked with the drug with no interference from tablet excipients or plasma components.
- || Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie
Retrospective data, Review, Journal: The Efficacy and Safety of Direct-Acting Antiviral Regimens for HCV/HIV Co-infection: A Systematic review and Network meta-analysis. (Pubmed Central) - Nov 6, 2020
Efficacy and safety of all-oral DAAs were in prospect for HIV/HCV co-infection patients. GZR/EBR ± RBV was the optimal combination recommended for HIV/HCV co-infected patients based on the excellent treatment effects and insignificant adverse events.
- || Olysio (simeprevir) / J&J, Medivir, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Cognitive assessment in patients with Hepatitis C submitted to treatment with Sofosbuvir and Simeprevir or Daclatasvir. (Pubmed Central) - Nov 6, 2020
GZR/EBR ± RBV was the optimal combination recommended for HIV/HCV co-infected patients based on the excellent treatment effects and insignificant adverse events. The treatment of the hepatitis C virus improved cognitive performance, especially in relation to memory.
- || Daklinza (daclatasvir) / BMS
Clinical, Journal: Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1. (Pubmed Central) - Oct 22, 2020
In contrast to data from other countries, RAS Q80K prevalence in Brazil is low in HCV subtype 1a. This study improves the knowledge of genetic barrier for resistance to PIs involving RASs in chronically infected patients and its possible impact on an unsuccessful treatment outcome, information that might be crucial to upcoming decisions of incorporation of new DAAs in Brazilian guidelines of antiviral therapy against HCV infection.
- | Olysio (simeprevir) / J&J, Medivir, Daklinza (daclatasvir) / BMS
Journal: Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms. (Pubmed Central) - Oct 21, 2020
The analytical performance of the newly proposed HPLC procedure was thoroughly validated according to ICH guidelines in terms of linearity, precision (RSD%, 0.39-1.57), accuracy (98.05-101.90%), specificity, limit of detection (LOD) (0.022-0.039 μg/mL), limit of quantification (LOQ) (0.067-0.118 μg/mL), and robustness. The validated HPLC method was successfully used to analyze the abovementioned drugs in their pure and dosage forms without interference from common excipients present in commercial formulations.
- || Olysio (simeprevir) / J&J, Medivir
Clinical, Journal: Clinical, Epidemiological, and Geospatial Characteristics of Patients Infected with Hepatitis C Virus Treated with Second-Generation Direct-Action Antivirals in a Reference Center in a Mesoregion of São Paulo State, Brazil. (Pubmed Central) - Oct 20, 2020
Genotypes 1a and 1b accounted for 75.7% of cases and the prevalent therapeutic regimen was sofosbuvir/simeprevir...Our data highlight the role of reference hospitals in Brazil's public health system in the treatment of HCV. Low incidence rates demonstrated the fragility of municipalities in the active search for patients.
- Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie
[VIRTUAL] DYNAMICS OF PROGRAMMED CELL DEATH-1 IN PERIPHERAL BLOOD IMMUNE CELL PROFILES AND RNA-SEQ ANALYSIS OF CHRONIC HEPATITIS C PATIENTS TREATED WITH DIRECT-ACTING ANTIVIRALS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_1000;
Thirteen of the patients had previously received antiviral treatments (interferon (IFN) in 6 cases, IFN/ribavirin in 6 cases, and IFN/ribavirin/simeprevir in 1 case)... The frequency of PD-1+ T cells decreased after DAA therapy in the SVR group, indicating that PD-1-related signals may be associated with the attainment of non-SVR in the absence of NS5A mutations.
- || grazoprevir (MK-5172) / Merck (MSD), doxycycline / Generic mfg., Pierre Fabre
PK/PD data, Journal: Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches. (Pubmed Central) - Oct 4, 2020
All these compounds not only showed excellent pharmacokinetic properties, absorption, metabolism, minimal toxicity and bioavailability but were also remain stabilized at the active site of proteins during the MD simulation. Thus, the identified lead compounds may act as potential molecules for the development of effective drugs against SARS-CoV-2 by inhibiting the envelope formation, virion assembly and viral pathogenesis.
- [VIRTUAL] Use of Need to HCV Retreatment As Cost-Effectiveness Analysis Criterion in Health Economics Analysis in Moscow () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_447;
The average cost of this AVT per patient as the first-line antiviral therapy was for 731.13€ lower than the ombitasvir/paritaprevir/ritonavir + dasabuvir (3D), and for 730.66€ higher than the elbasvir/grazoprevir (Elb/Grz).The need for retreatment for the Dac+Asu was 8.4%, and for the 3D, Elb/Grz and glecaprevir/pibrentasvir (Gle/Pib) - 0.58%, 0% and 0%, respectively. A greater difference from the average cost was recorded for the Sofosbuvir+Daclatasvir (Sof+Dac), Sofosbuvir+Simeprevir (Sof+Sim): which entailed the excess of the costs of treating one patient with this distribution of AVT and financial resources by 3143.52€ and 2348.28 €, respectively, which is 1.36 and 1, 27 times the average cost of all prices for antiviral treatment sets...The increase in the number of AVT attempts significantly increases the accumulated costs of treating a patient, which in turn leads to an increase in the burden on the budget of the healthcare system.
- | Olysio (simeprevir) / J&J, Medivir
Journal: Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study. (Pubmed Central) - Oct 1, 2020
A greater difference from the average cost was recorded for the Sofosbuvir+Daclatasvir (Sof+Dac), Sofosbuvir+Simeprevir (Sof+Sim): which entailed the excess of the costs of treating one patient with this distribution of AVT and financial resources by 3143.52€ and 2348.28 €, respectively, which is 1.36 and 1, 27 times the average cost of all prices for antiviral treatment sets...The increase in the number of AVT attempts significantly increases the accumulated costs of treating a patient, which in turn leads to an increase in the burden on the budget of the healthcare system. Simeprevir and pyronaridine were selected by the combination of virtual screening and molecular dynamics simulation approaches as a potential candidate for treatment of COVID-19.
- || paritaprevir/ritonavir (ABT-450/r) / AbbVie, Daklinza (daclatasvir) / BMS
Clinical, Journal, Real-World Evidence: Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil. (Pubmed Central) - Sep 30, 2020
Simeprevir and pyronaridine were selected by the combination of virtual screening and molecular dynamics simulation approaches as a potential candidate for treatment of COVID-19. SOF-based DAA regimens are effective and safe in the heterogeneous highly admixed Brazilian population and could remain an option for HCV treatment at least in low-income countries.
- | Journal: HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape. (Pubmed Central) - Sep 24, 2020
SOF-based DAA regimens are effective and safe in the heterogeneous highly admixed Brazilian population and could remain an option for HCV treatment at least in low-income countries. Position-80-substitutions had relatively low fitness cost and the potential to promote HCV escape from clinically relevant PIs in vitro, despite minor impact in classical short-term resistance assays.
- tacrolimus / Generic mfg.
[VIRTUAL] Acute Hepatitis B Infection in a Liver Transplant Recipient: Possible Role of IVIG () - Sep 15, 2020 - Abstract #ACG2020ACG_2932;
His medications included amlodipine, aspirin, propranolol, and tacrolimus...He started tenofovir alafenamide fumarate and had improvement of liver tests and HBV DNA 74,700 IU/mL after two weeks...Although false positive HBcAb may be observed in patients receiving IVIG, the detection of positive HBsAg or HBV DNA confirms active infection. Further research is needed to inform evidence-based guidance in monitoring HBV in patients receiving IVIG.
- | lumacaftor (VX-809) / Vertex, Olysio (simeprevir) / J&J, Medivir
Journal: An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors. (Pubmed Central) - Sep 10, 2020
We combined and integrated docking simulations, with molecular dynamics (MD), Supervised MD (SuMD) and Steered MD (SMD) simulations to identify a Spike protein - ACE2 interaction inhibitor. Our data showed that Simeprevir and Lumacaftor bind the receptor-binding domain of the Spike protein with high affinity and prevent ACE2 interaction.
- | grazoprevir (MK-5172) / Merck (MSD), paritaprevir/ritonavir (ABT-450/r) / AbbVie
FDA event, Journal: In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors. (Pubmed Central) - Sep 4, 2020
The leads also establish a network of hydrogen bonds and hydrophobic interactions with the key residues lining the active site pockets. The present findings suggest that these FDA approved antiviral drugs can be subjected to repurposing against SARS-CoV-2 infection after verifying the in silico results through in vitro and in vivo studies.
- | Journal, Combination therapy: Destabilizing the structural integrity of COVID-19 by caulerpin and its derivatives along with some antiviral drugs: An in silico approaches for a combination therapy. (Pubmed Central) - Aug 26, 2020
Also, molecular dynamics (MD) simulation indicates that binding of the combination therapy of simeprevir and the candidate studied compounds to the receptors was stable and had no major effect on the flexibility of the protein throughout the simulations and provided a suitable basis for our study. So, this study suggested that caulerpin and its derivatives could be used as a combination therapy along with lopinavir, simeprevir, hydroxychloroquine, chloroquine, and amprenavir for disrupting the stability of SARS-CoV2 receptor proteins to increase the antiviral activity of these drugs.
- | glecaprevir (ABT-493) / AbbVie, Ledipasvir (GS-5885) / Gilead, paritaprevir/ritonavir (ABT-450/r) / AbbVie
Journal: Drug repurposing using computational methods to identify therapeutic options for COVID-19. (Pubmed Central) - Aug 26, 2020
According to the results, glecaprevir, paritaprevir, simeprevir, ledipasvir, glycyrrhizic acid, TMC-310911, and hesperidin showed highly favorably free binding energies with all tested target proteins. The above-mentioned drugs can be regarded as candidates to treat COVID-19 infections, but further study on the efficiency of these drugs is also necessary.
- || Daklinza (daclatasvir) / BMS
Clinical, Journal: Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure. (Pubmed Central) - Aug 11, 2020
No dangerous or life-threatening adverse events were recorded. Retreatment of HCV genotype 4 patients with quadruple therapy is a good therapeutic option and achieves high response rates with minimal side effects.
- | Olysio (simeprevir) / J&J, Medivir, ledipasvir/sofosbuvir / Generic mfg.
Preclinical, Journal: Establishment of infectious genotype 4 cell culture-derived hepatitis C virus. (Pubmed Central) - Aug 4, 2020
Both ED43 QS-7M and TS-7M were sensitive to the neutralizing E2 antibodies HCV1 and AR3A and the direct-acting antivirals, simeprevir, ledipasvir and sofosbuvir. In conclusion, we established an infectious ED43 strain containing adaptive mutations, which is important for the analysis of HCV genotype-specific pathogenesis, development of pan-genotypic agents and analysis of drug resistance.
- | clarithromycin / Generic mfg., Sunvepra (asunaprevir) / BMS, ritonavir / Generic mfg.
Preclinical, Journal: Use of a Bile Salt Export Pump Knockdown Rat Susceptibility Model to Interrogate Mechanism of Drug Induced Liver Toxicity. (Pubmed Central) - Jul 29, 2020
The Bsep KD rat model has revealed differences in the effects on bile acid homeostasis among Bsep inhibitors that can best be monitored using measures of T3-BA and TCA-d4 in plasma. However, the phenotype caused by Bsep inhibition is complex due to the involvement of several compensatory mechanisms.
- || Copegus (ribavirin) / Bausch Health, Daklinza (daclatasvir) / BMS
Journal, Adverse drug reaction: Predictors of adverse drug reactions associated with ribavirin in direct-acting antiviral therapies for chronic hepatitis C. (Pubmed Central) - Jul 29, 2020
Direct-acting antiviral has been shown to be safe and effective. Therefore, use of ribavirin is questionable due to associated adverse reactions and similar efficacy to other treatments.
- | Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
Journal: Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. (Pubmed Central) - Jul 25, 2020
DCV-based antiviral therapy was well tolerated and resulted in a high SVR when combined with SOF either in pre-transplant and in OLT patients and in "difficult to treat" HCV genotypes. Regimens containing DCV in combination with NS3 protease inhibitors obtained suboptimal results.
- || Clinical, Journal: Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. (Pubmed Central) - Jul 18, 2020
Longer treatment duration increased likelihood of SVR. RBV increased likelihood of SVR among patients with GT3, previous DAA TF, or decompensated cirrhosis.
- | Olysio (simeprevir) / J&J, Medivir
Journal: Antiviral effects of simeprevir on multiple viruses. (Pubmed Central) - Jul 18, 2020
However, the inhibitory effects of Simeprevir on ZIKV, EV-A71 and HSV-1 were independent from IFN-β and ISG15. This study thus demonstrates that the application of Simeprevir can be extended to other viruses besides HCV.
- || Copegus (ribavirin) / Bausch Health, Daklinza (daclatasvir) / BMS
Clinical, Journal: Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy. (Pubmed Central) - Jul 16, 2020
In the current study, we aimed to assess the efficacy of different Sofosbuvir (SOF)-based antiviral regimens available in Egypt in the treatment of Pegylated interferon/Ribavirin (PEG-INF/RBV)-experienced chronic hepatitis C virus (HCV) patients...The patients received one of the following 3 regimens for 12 weeks; PEG-INF/SOF, Simeprevir/SOF (SIM/SOF), and Daclatasvir/SOF (DCV/SOF)...A SIM/SOF regimen provokes the highest SVR12 in PEG-INF/RBV-experienced chronic HCV patients. Retreatment with PEG-INF/SOF in PEG-INF/RBV-experienced chronic HCV patients has a high probability of treatment failure.
- || paritaprevir/ritonavir (ABT-450/r) / AbbVie
Clinical, Journal: Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naïve HCV positive Pakistani patients. (Pubmed Central) - Jul 16, 2020
Natural RAPs are common in chronic HCV patients infected with genotype 1a, 3a and 3b, the most prevalent subtypes in Pakistan. High prevalence of HCV NS3 RAPs suggested a large scale study of the NS3 gene before the introduction of NS3 protease inhibitors in Pakistan.
- | Olysio (simeprevir) / J&J, Medivir
Journal: Ring-Closing Metathesis on Commercial Scale: Synthesis of HCV Protease Inhibitor Simeprevir. (Pubmed Central) - Jul 8, 2020
N-Boc substitution on the diene precursor changes the site of insertion of the metathesis catalyst, and, consequently, the kinetic model of the ring closing metathesis (RCM), enabling a further increase in the macrocyclization efficiency under simulated high dilution (SHD) conditions. NMR of the inserted species of both 1st and 2nd generation RCM catalysts are reported and discussed.
- | Olysio (simeprevir) / J&J, Medivir, Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Journal: Synergistic anti-hepatitis C virus activity of Ruta angustifolia extract with NS3 protein inhibitor. (Pubmed Central) - Jul 8, 2020
The combination of extract and SMV and TVR mediated a synergistic effect. Conclusions These findings suggest that combining R. angustifolia extract with current anti-HCV drugs should be considered when developing alternative and complementary anti-HCV medicines.
- [VIRTUAL] EFFICACY, SAFETY AND FEASIBILITY OF TREATMENT OF CHRONIC HCV INFECTION WITH DIRECTLY ACTING AGENTS (DAAS) IN HCT RECIPIENTS - EBMT INFECTIOUS DISEASES WORKING PARTY STUDY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4947;
DAAs treatment was effective, safe and feasible in this cohort of mainly allogeneic HCT recipients with mild-to-moderate liver damage. Side effects were usually haematological and more frequent in case of ribavirin-containing regimens.
- [VIRTUAL] EFFICACY, SAFETY AND FEASIBILITY OF TREATMENT OF CHRONIC HCV INFECTION WITH DIRECTLY ACTING AGENTS (DAAS) IN HCT RECIPIENTS - EBMT INFECTIOUS DISEASES WORKING PARTY STUDY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4946;
DAAs treatment was effective, safe and feasible in this cohort of mainly allogeneic HCT recipients with mild-to-moderate liver damage. Side effects were usually haematological and more frequent in case of ribavirin-containing regimens.
- [VIRTUAL] EFFICACY, SAFETY AND FEASIBILITY OF TREATMENT OF CHRONIC HCV INFECTION WITH DIRECTLY ACTING AGENTS (DAAS) IN HCT RECIPIENTS - EBMT INFECTIOUS DISEASES WORKING PARTY STUDY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4945;
DAAs treatment was effective, safe and feasible in this cohort of mainly allogeneic HCT recipients with mild-to-moderate liver damage. Side effects were usually haematological and more frequent in case of ribavirin-containing regimens.
- | velpatasvir (GS-5816) / Gilead, Daklinza (daclatasvir) / BMS, elbasvir (MK-8742) / Merck (MSD)
Preclinical, Journal: Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. (Pubmed Central) - Jul 2, 2020
Side effects were usually haematological and more frequent in case of ribavirin-containing regimens. Therapies combining at least two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents may be effective for HCV-infected patients with NS5A-P32del.
- || Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie, Olysio (simeprevir) / J&J, Medivir, Daklinza (daclatasvir) / BMS
Clinical, Journal: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience. (Pubmed Central) - Jun 19, 2020
P4
Most adverse events reported were mild to moderate, with no deaths during the study. Multi-target direct-acting antiviral (DAA) combinations are efficient for retreatment of HCV patients after failure of SOF/DCV-based therapy in real-world management.ClinicalTrials.gov identifier: NCT02992457.
- || Clinical, Journal: JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-infected Patients without Cirrhosis: OMEGA-1. (Pubmed Central) - Jun 18, 2020
P2b
All randomized patients completed treatment. In HCV-infected patients, 6 and 8 weeks of treatment with JNJ-4178 resulted in SVR12 rates of 98.9% and 97.8%, respectively, and was well tolerated.
- || Clinical, Journal: Changing demographics among populations prescribed HCV treatment, 2013-2017. (Pubmed Central) - Jun 12, 2020
In HCV-infected patients, 6 and 8 weeks of treatment with JNJ-4178 resulted in SVR12 rates of 98.9% and 97.8%, respectively, and was well tolerated. In the United States, since the introduction of interferon-free HCV regimens, the patient population prescribed treatment has changed, becoming predominantly treatment-naïve, without cirrhosis, and treated in nonacademic centers.